ZIAGEN SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

ABACAVIR (ABACAVIR SULFATE)

Tilgjengelig fra:

VIIV HEALTHCARE ULC

ATC-kode:

J05AF06

INN (International Name):

ABACAVIR

Dosering :

20MG

Legemiddelform:

SOLUTION

Sammensetning:

ABACAVIR (ABACAVIR SULFATE) 20MG

Administreringsrute:

ORAL

Enheter i pakken:

240 ML

Resept typen:

Prescription

Terapeutisk område:

NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS

Produkt oppsummering:

Active ingredient group (AIG) number: 0137623002; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

1999-06-04

Preparatomtale

_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ZIAGEN, abacavir _
_July 2023 _
_ _
_Page 1 of 34_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ZIAGEN
abacavir tablets, 300 mg (as abacavir sulfate)
abacavir oral solution, 20 mg/ml (as abacavir sulfate)
Mfr. Standard
Antiretroviral Agent
ViiV Healthcare ULC
75 Queen Street, Suite 1400
Montreal, Quebec
Canada
H3C 2N6
Date of Initial Approval:
SEPT 10, 2001
Date of Revision:
JUL 05, 2023
Submission Control No: 272514
_©_
_2023 ViiV Healthcare group of companies or its licensor _
_Trademarks are owned by or licensed to the ViiV Healthcare group of
companies _
_ZIAGEN, abacavir _
_July 2023_
_ _
_Page 2 of 34 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General
07/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
TABLE OF CONTENTS
..........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
.........................................................................................................................
4
1.1
Pediatrics
...............................................................................................................................
4
1.2
Geriatrics
...............................................................................................................................
4
2
CONTRAINDICATIONS
............................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
........................................................................
5
4
DOSAGE AND ADMINISTRATION
............................................................................................
5
4.1
Dosing Considerations
.....................................................................................................